GSK’s Two-Speed Strategy: Broad Sourcing and Selective Bets

Why It Matters

The strategy lets GSK diversify its pipeline without over‑committing capital, supporting long‑term growth targets while mitigating the impact of patent expirations on core franchises.

Key Takeaways

• GSK splits early deals from later-stage acquisitions.
• Specialty medicines now >40% of sales.
• HIV and vaccines drive core growth.
• $950M 35Pharma buy adds pulmonary hypertension asset.
• Broad external sourcing reduces discovery risk.

Pulse Analysis

GSK’s post‑Haleon re‑orientation underscores a broader industry trend: large biopharma firms are sharpening their focus on high‑margin specialty medicines and vaccines while shedding consumer‑health distractions. By 2025, specialty medicines and vaccines together contributed roughly $30 billion of GSK’s $43.7 billion revenue, with HIV alone delivering $10.3 billion. This concentration provides a clearer growth narrative and positions the company to meet its ambitious $53.5 billion sales goal for 2031, but it also heightens exposure to patent cliffs, especially in the lucrative dolutegravir‑based HIV portfolio.

To balance the need for new products with the high failure rates of early‑stage research, GSK has adopted a two‑speed pipeline model. At the discovery end, it signs low‑up‑front collaborations with innovators like Muna Therapeutics and Relation Therapeutics, tapping spatial transcriptomics and AI‑driven genetics to generate validated targets. Parallel deals expand its modality toolbox—RNA‑splicing modulators from Rgenta and antibody‑drug conjugates via Duality Biologics—allowing GSK to stay at the forefront of emerging therapeutic platforms without bearing full development risk. These partnerships act as a funnel, feeding a steady stream of vetted candidates into the later‑stage pipeline.

When scientific validation reaches a more advanced stage, GSK shifts to higher‑commitment transactions, exemplified by the $950 million acquisition of 35Pharma and the purchase of a phase‑2‑ready anti‑TSLP antibody from Aiolos Bio. Such moves bring assets closer to market, leveraging existing commercial expertise in respiratory and autoimmune spaces. The challenge lies in differentiating these late‑stage assets from incumbent products and ensuring they can generate meaningful revenue before the next wave of exclusivity losses. Ultimately, the success of GSK’s dual‑track strategy will hinge on disciplined deal selection and the ability to translate external innovations into profitable, differentiated therapies.